Fig. 3From: Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysisPredicted vaccine efficacy against SARS-CoV-2 variants of concern after fully vaccinated with half-dose vaccines. Vaccine efficacy against symptomatic infections after full vaccinations (i.e., one dose non-replicating viral vector and two doses for the rest) of half-dose is shown, with the complete dose-dependent effectiveness shown in Additional file 1: Fig. S8. A-E for Alpha, Beta, Gamma, Delta, and OmicronBack to article page